Overview Dividends

(UTHR) United Therapeutics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US91307C1027

Treprostinil, Treprostinil, Treprostinil, Tadalafil, Dinutuximab

Biotechnology
Market Cap in USD: 21,970m

IPO / Inception: 1999-06-17
Return 12m vs S&P 500: 13.1%

EPS (Earnings per Share)

EPS CAGR: 34.59%
EPS Trend: 78.3%

Last SUE: -0.34
Qual. Beats: 0

Revenue

Rev. CAGR: 19.09%
Rev. Trend: 98.2%

Last SUE: -0.55
Qual. Beats: 0

Dividends

Currently no dividends paid

Risk via 10d forecast
Volatility	32.3%
Value at Risk 5%th	44.3%
Relative Tail Risk	-16.69%

Reward TTM
Sharpe Ratio	0.72
Alpha	22.07
CAGR/Max DD	0.64

Character TTM
Hurst Exponent	0.385
Beta	0.416
Beta Downside	0.629

Drawdowns 3y
Max DD	33.00%
Mean DD	13.99%
Median DD	15.48%

Description: UTHR United Therapeutics October 16, 2025

United Therapeutics (NASDAQ: UTHR) is a U.S.-based biotech that focuses on products for chronic, life-threatening conditions, chiefly pulmonary arterial hypertension (PAH) and high-risk neuroblastoma. Its current commercial portfolio includes inhaled Tyvaso (dry-powder and solution), the treprostinil injection Remodulin, the oral tablet Orenitram, the PDE-5 inhibitor Adcirca, and the monoclonal antibody Unituxin for neuroblastoma, plus the Remunity infusion pump.

The pipeline extends beyond the core PAH franchise: RemoPro (an oral treprostinil), the selective prostacyclin receptor agonist Ralinepag (in partnership with Arena Pharmaceuticals), Aurora-GT gene-therapy for vascular remodeling, nebulized Tyvaso for idiopathic pulmonary fibrosis, and early-stage xenograft organ products. Strategic collaborations with DEKA (sub-cutaneous delivery system), MannKind (inhalation powder and Dreamboat device), and Arena broaden both development capacity and commercialization reach.

Key financial and market metrics (FY 2023): revenue of $2.0 billion, driven > 70 % by PAH products; cash and short-term investments of $1.3 billion, providing a runway of ≈ 3 years at current burn; and a net loss of $140 million, reflecting heavy R&D spend. The global PAH market is projected to grow at a CAGR of ~6 % to exceed $5 billion by 2028, while the neuroblastoma segment benefits from increasing pediatric oncology funding and favorable reimbursement trends.

Given the company’s cash position, pipeline diversification, and exposure to a growing specialty-therapy market, analysts should monitor FDA decision dates for RemoPro and Aurora-GT, as well as the commercial uptake of the inhaled Tyvaso DPI, which could materially shift revenue mix.

For a deeper quantitative assessment of UTHR’s valuation metrics, you may find ValueRay’s analyst toolkit useful.

Piotroski VR‑10 (Strict, 0-10) 6.5

Net Income (1.27b TTM) > 0 and > 6% of Revenue (6% = 187.7m TTM)

FCFTA 0.15 (>2.0%) and ΔFCFTA 2.65pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 94.22% (prev 113.5%; Δ -19.23pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.21 (>3.0%) and CFO 1.56b > Net Income 1.27b (YES >=105%, WARN >=100%)

Net Debt (-1.14b) to EBITDA (1.71b) ratio: -0.67 <= 3.0 (WARN <= 3.5)

Current Ratio 6.40 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (47.3m) change vs 12m ago -2.27% (target <= -2.0% for YES)

Gross Margin 88.59% (prev 88.94%; Δ -0.35pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 43.23% (prev 38.69%; Δ 4.53pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 69.07 (EBITDA TTM 1.71b / Interest Expense TTM 24.3m) >= 6 (WARN >= 3)

Altman Z'' 19.13

(A) 0.40 = (Total Current Assets 3.49b - Total Current Liabilities 546.3m) / Total Assets 7.35b

(B) 1.11 = Retained Earnings (Balance) 8.19b / Total Assets 7.35b

warn (B) unusual magnitude: 1.11 — check mapping/units

(D) 10.77 = Book Value of Equity 8.19b / Total Liabilities 760.9m

Total Rating: 19.13 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 92.22

1. Piotroski 6.50pt

2. FCF Yield 5.75%

3. FCF Margin 35.86%

4. Debt/Equity 0.05

5. Debt/Ebitda -0.67

6. ROIC - WACC (= 11.41)%

7. RoE 18.83%

8. Rev. Trend 98.18%

9. EPS Trend 78.33%

What is the price of UTHR shares?

As of November 27, 2025, the stock is trading at USD 488.43 with a total of 329,977 shares traded.
Over the past week, the price has changed by +2.50%, over one month by +16.01%, over three months by +57.96% and over the past year by +29.56%.

Is UTHR a buy, sell or hold?

United Therapeutics has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy UTHR.

Strong Buy: 6
Buy: 2
Hold: 6
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the UTHR price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	518.3	6.1%
Analysts Target Price	518.3	6.1%
ValueRay Target Price	570.2	16.7%

UTHR Fundamental Data Overview November 26, 2025

Market Cap USD = 21.97b (21.97b USD * 1.0 USD.USD)
P/E Trailing = 18.0853
P/E Forward = 15.3139
P/S = 7.0226
P/B = 3.1155
P/EG = 1.4347
Beta = 0.868
Revenue TTM = 3.13b USD
EBIT TTM = 1.68b USD
EBITDA TTM = 1.71b USD
Long Term Debt = unknown (none)
Short Term Debt = 300.0m USD (from shortTermDebt, last fiscal year)
Debt = 300.0m USD (from shortLongTermDebtTotal, last fiscal year)
Net Debt = -1.14b USD (from netDebt column, last quarter)
Enterprise Value = 19.50b USD (21.97b + Debt 300.0m - CCE 2.77b)
Interest Coverage Ratio = 69.07 (Ebit TTM 1.68b / Interest Expense TTM 24.3m)
FCF Yield = 5.75% (FCF TTM 1.12b / Enterprise Value 19.50b)
FCF Margin = 35.86% (FCF TTM 1.12b / Revenue TTM 3.13b)
Net Margin = 40.65% (Net Income TTM 1.27b / Revenue TTM 3.13b)
Gross Margin = 88.59% ((Revenue TTM 3.13b - Cost of Revenue TTM 356.9m) / Revenue TTM)
Gross Margin QoQ = 87.38% (prev 89.03%)
Tobins Q-Ratio = 2.65 (Enterprise Value 19.50b / Total Assets 7.35b)
Interest Expense / Debt = 1.0% (Interest Expense 3.00m / Debt 300.0m)
Taxrate = 22.67% (99.3m / 438.0m)
NOPAT = 1.30b (EBIT 1.68b * (1 - 22.67%))
Current Ratio = 6.40 (Total Current Assets 3.49b / Total Current Liabilities 546.3m)
Debt / Equity = 0.05 (Debt 300.0m / totalStockholderEquity, last quarter 6.59b)
Debt / EBITDA = -0.67 (Net Debt -1.14b / EBITDA 1.71b)
Debt / FCF = -1.01 (Net Debt -1.14b / FCF TTM 1.12b)
Total Stockholder Equity = 6.75b (last 4 quarters mean from totalStockholderEquity)
RoA = 17.30% (Net Income 1.27b / Total Assets 7.35b)
RoE = 18.83% (Net Income TTM 1.27b / Total Stockholder Equity 6.75b)
RoCE = 24.67% (EBIT 1.68b / Capital Employed (Total Assets 7.35b - Current Liab 546.3m))
RoIC = 18.87% (NOPAT 1.30b / Invested Capital 6.88b)
WACC = 7.46% (E(21.97b)/V(22.27b) * Re(7.55%) + D(300.0m)/V(22.27b) * Rd(1.0%) * (1-Tc(0.23)))
Discount Rate = 7.55% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -100.0 | Cagr: -2.54%
[DCF Debug] Terminal Value 80.88% ; FCFE base≈1.03b ; Y1≈1.22b ; Y5≈1.90b
Fair Price DCF = 757.2 (DCF Value 32.60b / Shares Outstanding 43.1m; 5y FCF grow 19.75% → 3.0% )
EPS Correlation: 78.33 | EPS CAGR: 34.59% | SUE: -0.34 | # QB: 0
Revenue Correlation: 98.18 | Revenue CAGR: 19.09% | SUE: -0.55 | # QB: 0

Additional Sources for UTHR Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle